Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -19.74% is 154% below its 5-year average of 36.63%, around the middle of its 5-year range (-124.05%–96.08%).
558.49% below its 12-month average of -3.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 61.50%.
GROSS MARGIN
-19.74%
GROSS MARGIN AVG TTM
-3.00%
GROSS MARGIN AVG 3Y
40.49%
GROSS MARGIN AVG 5Y
36.63%
GROSS MARGIN AVG 10Y
41.23%
GROSS MARGIN AVG 15Y
46.98%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-558.49%
CURRENT VS 3Y AVG
-148.75%
CURRENT VS 5Y AVG
-153.89%
CURRENT VS 10Y AVG
-147.88%
CURRENT VS 15Y AVG
-142.02%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-147.70%
vs the sector median at left
Sintx Technologies, Inc.
Market Cap
$13.78M
Gross Margin
-19.74%
TTM Avg
-3.00%
3Y Avg
40.49%
5Y Avg
36.63%
Market Cap
$13.93M
Gross Margin
64.68%
TTM Avg
63.93%
3Y Avg
63.08%
5Y Avg
61.52%
Market Cap
$13.92M
Gross Margin
84.15%
TTM Avg
52.79%
3Y Avg
35.70%
5Y Avg
25.98%
Market Cap
$13.33M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.30M
Gross Margin
-486.44%
TTM Avg
-208.47%
3Y Avg
-109.22%
5Y Avg
-72.81%
Market Cap
$14.73M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-2.45%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sintx Technologies, Inc. (SINT) | $13.78M | -19.74% | -3.00% | 40.49% | 36.63% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.01M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.93M | 64.68% | 63.93% | 63.08% | 61.52% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $13.92M | 84.15% | 52.79% | 35.70% | 25.98% |
| Passage Bio, Inc. (PASG)vs › | $13.40M | 0.00% | 0.00% | 0.00% | 0.00% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.33M | 0.00% | 0.00% | 0.00% | 0.00% |
| Optimi Health Corp. (OPTH)vs › | $13.30M | -486.44% | -208.47% | -109.22% | -72.81% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.73M | 0.00% | 0.00% | 0.00% | -2.45% |
| IN8bio, Inc. (INAB)vs › | $13.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.73M | 18.76% | 9.38% | 50.69% | 33.79% |
Gross Margin
-19.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 61.50% |
| 2026-03-31 | -3.16% |
| 2025-12-31 | -124.05% |
| 2025-09-30 | 44.71% |
| 2025-06-30 | 6.00% |
| 2025-03-31 | 33.33% |
| 2024-12-31 | 71.59% |
| 2024-09-30 | 42.78% |
| 2024-06-30 | 40.74% |
| 2024-03-31 | 27.83% |
| 2023-12-31 | 50.67% |
| 2023-09-30 | 30.36% |
| 2023-06-30 | 79.53% |
| 2023-03-31 | 50.83% |
| 2022-12-31 | 96.08% |
| 2022-09-30 | 48.55% |
| 2022-06-30 | 17.50% |
| 2022-03-31 | 20.79% |
| 2021-12-31 | 24.24% |
| 2021-09-30 | 20.50% |
| 2021-06-30 | 27.72% |
| 2021-03-31 | 39.60% |
| 2020-12-31 | 19.83% |
| 2020-09-30 | 19.70% |
| 2020-06-30 | 20.10% |
| 2020-03-31 | 19.81% |
| 2019-12-31 | 25.79% |
| 2019-09-30 | 12.72% |
| 2019-06-30 | 20.36% |
| 2019-03-31 | 18.56% |
| 2018-12-31 | 41.05% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 74.45% |
| 2018-03-31 | 77.13% |
| 2017-12-31 | -46.30% |
| 2017-09-30 | 52.37% |
| 2017-06-30 | 77.49% |
| 2017-03-31 | 74.86% |
| 2016-12-31 | 69.82% |
| 2016-09-30 | 77.35% |
| 2016-06-30 | 74.72% |
| 2016-03-31 | 78.60% |
| 2015-12-31 | 66.14% |
| 2015-09-30 | 66.08% |
| 2015-06-30 | 71.49% |
| 2015-03-31 | 67.91% |
| 2014-12-31 | 47.21% |
| 2014-09-30 | 67.67% |
| 2014-06-30 | 72.53% |
| 2014-03-31 | 71.47% |
| 2013-12-31 | 64.41% |
| 2013-09-30 | 67.21% |
| 2013-06-30 | 78.04% |
| 2013-03-31 | 62.95% |
| 2012-12-31 | 47.76% |
| 2012-09-30 | 92.80% |
